Во Всемирном докладе о наркотиках содержится комплексная информация по положению в области незаконных наркотиков. В нем представлены подробные оценки и тенденци..., относящиеся к производству, незаконному обороту и потреблению на рынках опиума/героина, коки/кокаина, каннабиса и стимуляторов амфетаминового ряда. Масштабы проблемы наркотиков удается ограничивать, но существуют признаки того, что стабилизация, достигнутая за последние несколько лет, может подвергаться риску. Среди этих признаков – расширение культивирования в 2007 году опийного мака и коки, некоторый прирост потребления в развивающихся странах и в определенной степени развитие новых схем незаконного оборота. Также отмечалось обнадеживающее сокращение некоторых из основных потребительских рынков.
more
Most African Countries Avoid Major Economic Loss but Impact on Guinea, Liberia, Sierra Leone Remains Crippling
Rapport mondial sur les drogues 2018
The principles and practice of the surgical lmanagment of wounds produced by missiles or explosions
This book is aimed at policymakers in ministries of agriculture and national agricultural research institutes, as well as multilateral development banks and the private sector and provides guidance on various technology strategies and which to pursue as competition grows for land, water, and energy ...across productive sectors and even increasingly across borders. Climate change, population, and income growth will drive food demand in the coming decades. Food prices are also expected to significantly increase between 2005 and 2050 and the number of people at risk of hunger in the developing world would grow from 881 million in 2005 to more than a billion people by 2050. This book endeavors to respond to the challenge of growing food sustainably without degrading our natural resource bas
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
The ethical governance of research assumes the existence of a national entity (or subnational if applicable, according to the constitution of a country) in charge of supervising the research ethics committees (RECs) that review and monitor research with human beings. This supervision includes the ac...creditation of the RECs that authorize them to operate in the jurisdiction in question. This tool has the objective of facilitating the work of accreditation of RECs and ensuring that it is carried out in accordance with international ethical standards.
more